Blau Farmacêutica Balance Sheet Health
Financial Health criteria checks 6/6
Blau Farmacêutica has a total shareholder equity of R$2.1B and total debt of R$509.8M, which brings its debt-to-equity ratio to 24.5%. Its total assets and total liabilities are R$3.2B and R$1.2B respectively. Blau Farmacêutica's EBIT is R$265.9M making its interest coverage ratio 18.6. It has cash and short-term investments of R$431.9M.
Key information
24.5%
Debt to equity ratio
R$509.83m
Debt
Interest coverage ratio | 18.6x |
Cash | R$431.95m |
Equity | R$2.08b |
Total liabilities | R$1.16b |
Total assets | R$3.24b |
Recent financial health updates
Recent updates
Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 07Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up
Nov 06Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings
Aug 29Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?
Jun 28Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop
Feb 01What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Financial Position Analysis
Short Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its short term liabilities (R$455.8M).
Long Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its long term liabilities (R$701.0M).
Debt to Equity History and Analysis
Debt Level: BLAU3's net debt to equity ratio (3.7%) is considered satisfactory.
Reducing Debt: BLAU3's debt to equity ratio has reduced from 91.5% to 24.5% over the past 5 years.
Debt Coverage: BLAU3's debt is well covered by operating cash flow (65.2%).
Interest Coverage: BLAU3's interest payments on its debt are well covered by EBIT (18.6x coverage).